FDA Rejects RP-1 in Melanoma: What the Deep Dive Will Unpack
The FDA has declined to approve RP-1 for melanoma. Medscape's data deep dive walks through what the agency's reasoning means for the melanoma drug pipeline and clinical practice.
Topic
Drug Approval
Topic
Drug Approval
FDA Advisers Back Replimune Skin Cancer Drug; Shares Surge
Replimune shares surged after FDA advisers backed the company's skin cancer drug, an oncolytic immunotherapy now awaiting a forma…
Newly Approved Oral Psoriasis Therapy Expands Treatment Options
Regulators have approved a new oral psoriasis therapy, adding a pill-based systemic option to the plaque psoriasis armamentarium.…
FDA Advisory Committee Backs Melanoma Therapy After Two Rejections
An advanced melanoma therapy that failed twice in prior reviews has won a favorable FDA advisory committee vote, reviving its pat…
Vusolimogene Oderparepvec Secures Approval for Advanced Melanoma
Regulators have approved vusolimogene oderparepvec for advanced melanoma, adding an oncolytic viral therapy to the systemic optio…